Format

Send to

Choose Destination
Cell Stem Cell. 2017 Jan 5;20(1):13-17. doi: 10.1016/j.stem.2016.12.003.

Achieving Efficient Manufacturing and Quality Assurance through Synthetic Cell Therapy Design.

Author information

1
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
2
Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada; CCRM, Toronto, ON M5G 1L5, Canada.
3
Dark Horse Consulting, Campbell, CA 95008, USA.
4
CCRM, Toronto, ON M5G 1L5, Canada.
5
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada; CCRM, Toronto, ON M5G 1L5, Canada; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 3E1, Canada; Medicine by Design: A Canada First Research Excellence Fund Program, University of Toronto, Toronto, ON M5S 3E1, Canada. Electronic address: peter.zandstra@utoronto.ca.

Abstract

New methods to manipulate gene and cell state can be used to engineer cell functionality, simplify quality assessment, and enhance manufacturability. These strategies could help overcome unresolved cell therapy manufacturing challenges and complement frameworks to design quality into these complex cellular systems, ultimately increasing patient access to living therapeutics.

PMID:
28061350
DOI:
10.1016/j.stem.2016.12.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center